Randomised comparison of amniocentesis and transabdominal and transcervical chorionic villus sampling

Smidt‐Jensen, Steen; Philip, John; Lundsteen, Claes; Permin, M.; Zachary, Julia; Fowler, Sarah E.

doi:10.1016/0140-6736(92)92946-d

Cited by 175 publications

(112 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, operators must be skilled in both methods. Both techniques appear to be comparably efficient between 8 and 12 weeks, when the overall success rate after two sampling device insertions is considered to be very near to 100% (Philip et al,2004).This efficiency has been confirmed in three national randomized trials of transabdominal vs.transcervical CVS (Brambati et al,1991;Jackson et al,1992;Smidt-Jensen et al,1992). Although the data appear to confirm that the two techniques are equally effective in obtaining adequate amounts of chorionic tissue, transabdominal needling entailed a significantly smaller proportion of repeated device insertions (3.3 vs. 10.3%) and of low weight specimens (3.2 vs. 4.9%).…”

Section: Transcervical Versus Transabdominal Chorionic Villus Samplingmentioning

confidence: 62%

Invasive Prenatal Diagnosis

Pop-Trajkovic¹,

Antić²,

Kopitović³

2012

Prenatal Diagnosis - Morphology Scan and Invasive Methods

View full text Add to dashboard Cite

Section: Transcervical Versus Transabdominal Chorionic Villus Samplingmentioning

confidence: 62%

Invasive Prenatal Diagnosis

Pop-Trajkovic¹,

Antić²,

Kopitović³

2012

Prenatal Diagnosis - Morphology Scan and Invasive Methods

View full text Add to dashboard Cite

“…[120][121][122] However, this has not been a universal conclusion. 123 A recent meta-analysis of 3 randomized controlled trials comparing first-trimester CVS and midtrimester amniocentesis concluded that pregnancy loss was slightly more common after CVS (odds ratio, 1.33; 95% confidence interval, 1.17-1.52).…”

Section: Is Earlier Diagnosis Important?mentioning

confidence: 95%

Sonographic screening for fetal aneuploidy: first trimester.

Souter¹,

Nyberg²

2001

J of Ultrasound Medicine

View full text Add to dashboard Cite

Objectives. Screening for fetal aneuploidy is now possible during the first trimester using sonographic and biochemical markers. The aim of this review was to summarize the efficacy and use of nuchal translucency in screening for fetal aneuploidy, especially fetal Down syndrome, and other anomalies. Methods. We reviewed available literature regarding first-trimester screening. This includes more than 16 studies of nuchal translucency as a marker for fetal aneuploidy published since 1995. Results. Although early studies showed wide variation in detection of fetal Down syndrome when using nuchal translucency, more recent studies showed sensitivities of approximately 70% to 80%, for a 5% false-positive rate. Increased nuchal translucency has also been found to be a marker for other aneuploidies, including trisomy 18, trisomy 13, and Turner syndrome. Maternal serum biochemical screening can be used as a test for aneuploidy during the first trimester. The 2 maternal serum markers that appear to be most useful in the late first trimester are the free β subunit of human chorionic gonadotropin and pregnancy-associated plasma protein A. Together with maternal age, these markers yield a detection rate for trisomy 21 of approximately 60%, for a 5% false-positive rate. Because sonographic and biochemical markers appear to be largely independent, their combined risk results in improved detection rates compared with either method alone. As a result, the combination of nuchal translucency, biochemical markers, and maternal age has achieved a detection rate of approximately 85%, for a 5% false-positive level for detection of trisomy 21. A newly proposed "integrated" approach using a panel of first-and second-trimester markers suggests that further improvement in the screening performance is possible. A number of questions regarding first-trimester screening remain. We address some of these questions: Is first-trimester screening more effective than second-trimester screening? How to account for intrauterine lethality? Is earlier diagnosis important, and will it be accepted by patients? Is first-trimester screening cost-effective? How should first-trimester screening be interpreted with second-trimester tests? Conclusions. Despite encouraging data and general enthusiasm for first-trimester screening for fetal Down syndrome and other aneuploidies, a number of questions remain about its implementation in the United States. Multicenter studies currently under way should help answer some of these questions.

show abstract

“…17,18 The success of cytogenetic diagnosis is slightly lower for CVS versus amniocentesis. In particular, CVS is associated with an increased frequency of placental mosaicism, which is a cytogenetic abnormality detected in the CVS sample but not found in the fetus or newborn.…”

Section: Cvsmentioning

confidence: 99%

Prenatal Screening and Diagnosis for Pediatricians

Cunniff¹

2004

Pediatrics

View full text Add to dashboard Cite

ABSTRACT. The pediatrician who cares for a child with a birth defect or genetic disorder may be in the best position to alert the family to the possibility of a recurrence of the same or similar problems in future offspring. The family may wish to know about and may benefit from methods that convert probability statements about recurrence risks into more precise knowledge about a specific abnormality in the fetus. The pediatrician also may be called on to discuss abnormal prenatal test results as a way of understanding the risks and complications that the newborn infant may face. Along with the increase in knowledge brought about by the sequencing of the human genome, there has been an increase in the technical capabilities for diagnosing many chromosome abnormalities, genetic disorders, and isolated birth defects in the prenatal period. The purpose of this report is to update the pediatrician about indications for prenatal diagnosis, current techniques used for prenatal diagnosis, and the status of maternal screenings for detection of fetal abnormalities.

show abstract

Randomised comparison of amniocentesis and transabdominal and transcervical chorionic villus sampling

Cited by 175 publications

References 22 publications

Invasive Prenatal Diagnosis

Invasive Prenatal Diagnosis

Sonographic screening for fetal aneuploidy: first trimester.

Prenatal Screening and Diagnosis for Pediatricians

Contact Info

Product

Resources

About